Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03999983

Acronym

VOTER

Enrollment

150

Registered

2019-06-27

Start date

2019-11-19

Completion date

2026-12-31

Last updated

2025-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vertebral Artery Stenosis

Brief summary

A retrospective and prospective registry of patients admitted for stroke and evidence of Vertebral Artery Origin Stenosis (VAOS).

Detailed description

A retrospective registry of stenting plus medical management for the prevention of recurrent stroke in patients with symptomatic Vertebral Artery origin Stenosis (VAOS). This study is collecting information on clinical outcomes up to 18 months post-treatment. On January 6, 2025, VOTER was changed from prospective to retrospective.

Interventions

OTHERObservational Prospective Registry

This is a prospective registry looking at patients admitted for stroke with evidence of Vertebral Artery Origin Stenosis. Patients clinical outcomes will be collected at 30 days and 1-year post-treatment and angiographic outcomes at 1-year post-treatment

Study design

Observational model

CASE_ONLY

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

1. Patients between 18 and 90 years of age 2. Patient has experienced a posterior circulation ischemic event 3. Patient has angiographically confirmed bilateral vertebral artery origin disease (Hypoplasia, occlusion, or stenosis). 4. Patient has \>50% stenosis on the side being targeted for therapy

Exclusion criteria

1. Pregnant women 2. Contrast Indication to the use of anti-platelet drugs 3. There is tandem vertebral or basilar artery stenosis 4. The serum creatinin is \>2.5 5. Baseline modified Rankin score is \>3 6. \< 5 years life expectancy

Design outcomes

Primary

Measure	Time frame	Description
Incidence of recurrent stroke or death	1 Year post-treatment	Recurrent stroke of any type or death from any cause

Secondary

Measure	Time frame	Description
Incidence of Restenosis	1 Year post-treatment	Restenosis in VAOS patients treated with drug-eluting stents.

Countries

United States

Contacts

Primary ContactRandall Edgell, MD

randall.edgell@health.slu.edu314-977-3129

Backup ContactMollie Hoffmeyer, RN, BSN

mollie.hoffmeyer@health.slu.edu314-617-3313

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026